ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0554

Sensitivity of Urinary N-Terminal Osteopontin-to-Creatinine Ratio in Predicting Renal Function Loss

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Sun, Ling, Xuzhou City Centre Hospital, Xuzhou, Jiangsu, China
  • Sinha, Satyesh K., UCLA, University of California Los Angeles, Los Angeles, California, United States
  • Lusis, Aldons J., UCLA, University of California Los Angeles, Los Angeles, California, United States
  • Nicholas, Susanne B., UCLA, University of California Los Angeles, Los Angeles, California, United States

Group or Team Name

  • Metabolic Syndrome In Men (METSIM)

Osteopontin (OPN) is a multifunctional protein that gets cleaved to create N- terminal OPN (ntOPN). ntOPN has been reported in urine in kidney diseases but little is known about the sensitivity of ntOPN to creatinine ratio (ntOCR) as a urinary biomarker compared to the urinary albumin-to-creatinine ratio (UACR). This study is aimed to explore the prognostic value of ntOCR regarding renal function loss in a subset of the metabolic syndrome in men (METSIM) study with a high incidence of diabetes mellitus.


The METSIM study recruited 10,197 Finnish men between 2005 and 2010 and reexamined participants at two 5-year follow-ups. We performed a prospective observational study of a METSIM cohort of 137 participants, 45-72 years old at entry, with available urine at baseline and the first follow-up period, after 3.8±1.4 years. Serum and urinary levels of the ntOPN were quantified by ELISA. Using estimated glomerular filtration rate (eGFR), UACR and urine albumin excretion (UAE) of progressors and non-progressors, data were analyzed by paired t-test and Wilcoxon matched-pairs signed-rank test. The area under the receiver-operating characteristics (ROC) curve (AUC) was used to assess the sensitivity/specificity of variables in predicting the progression of CKD. Pearson correlation coefficient was performed to detect the relationships between the values of variables.


Compared to the CKD non-progressors, the progressors had significantly higher eGFR at baseline (96.95 vs. 87.75 mL/min/1.73 m2, p<0.00) and lower eGFR at follow-up (86.11 vs. 91.40 mL/min/1.73 m2, p=0.01). The baseline urine levels of ntOCR were higher in progressors than non-progressors (6.83 vs 3.68 pmol/mg, p=0.05). There were no differences in the UAE, UACR, or serum ntOPN between the two groups. However, baseline urinary ntOCR predicted renal function loss with an AUC of 0.60 (p=0.05), and the change between baseline and follow-up had a higher AUC value of 0.63 (p=0.01).


Our study suggests that urinary ntOCR might be a promising predictive biomarker for renal function loss in a population with high rates of metabolic syndrome and diabetes. Measurements at the second METSIM follow-up may confirm this observation. Further studies are needed in females, larger size populations, and long-term follow up.


  • Other NIH Support